Nonpeptide small-molecule medicine · U.S.-focused educational profile
Foundayo
An oral, nonpeptide GLP-1 receptor agonist and the active ingredient in the FDA-approved Foundayo product.[1]
How to use this page: match the exact product, form, route, population, and use before applying any evidence. This profile does not assess individual suitability.
This page identifies the named substance and the published context around it. A brand name, alias, salt, fragment, or cosmetic ingredient may not represent the same evidence or product.
Evidence can change with a product's chemical form, formulation, route, ingredients, and manufacturing. Similar names do not establish that two products are equivalent.
These are published research or product contexts. They are not indications selected for an individual and do not say that a compound is suitable for a particular person.
A formulation is the specific product form, such as a tablet, cream, or injection. A route describes how it reaches the body. The entries below describe the cited product or research context; they are not instructions for use.
[1]Routes shown apply only to the named published or investigational formulation; they are not instructions for use.
[1]Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.
Human evidence in specific contexts. Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific.
GLP-1, metabolic and weight-management
Randomized clinical studies in FDA labeling support Foundayo for chronic weight management in the labeled adult population.
This is a newly approved medicine with less postmarketing experience than older GLP-1 medicines. Rare events, use outside labeled populations, and comparisons with established products remain less certain.
Open source [1]More human evidence does not automatically mean better results for a different product, route, population, or purpose. Limited or missing evidence does not prove that a compound has no biological activity; it means the relevant clinical question has not been established by the published material reviewed here.
Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.
The label describes nonclinical pharmacology and toxicology. Unlike some GLP-1 receptor agonists, orforglipron was not pharmacologically active in the rodent species used for the thyroid findings discussed in the boxed warning; human relevance of the class concern remains uncertain.[1]
Preclinical findings do not establish outcomes in people.
Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.
Labeled risks include gastrointestinal reactions, pancreatitis, kidney injury related to volume depletion, hypoglycemia, hypersensitivity, diabetic-retinopathy complications, gallbladder disease, interactions with some medicines, and a boxed thyroid C-cell tumor warning.
The cited product label describes risks for a specific approved product and use. It is not a complete guide to every product or individual situation.Open source [1]This is a newly approved medicine with less postmarketing experience than older GLP-1 medicines. Rare events, use outside labeled populations, and comparisons with established products remain less certain.
The answer can change with the product, formulation, route, population, duration, and use being discussed.Open source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are not the same thing. A risk mentioned in one product label may not apply to every formulation, and an uncertainty is not proof of either safety or harm.
This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.
At least one FDA-approved product exists, but approval applies only to the named product, formulation, route, population, and use in its label.
Foundayo is FDA approved for chronic weight management in adults with obesity or adults with overweight and at least one weight-related condition, within the full labeled context.
Specific product form or route is not separately published in this status record.
Open source contextThe date above is the date attached to the published status record or source context. It is not necessarily the original approval date.
These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.
PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.
FOUNDAYO prescribing information
DailyMed. FOUNDAYO (orforglipron) prescribing information. Initial U.S. approval 2026.
National Library of Medicine / Eli Lilly · Published Apr 1, 2026 · Accessed Jul 22, 2026 · Prescribing information
Open sourcePeptideGrid separates identity, human evidence, laboratory and animal findings, risks, uncertainty, and product-specific U.S. status. Missing information stays marked as unpublished instead of being inferred. The Library is an educational source-and-structure resource, not a clinician review or a suitability assessment.
